Dow Jones

40,211.72

0.53%

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

CGEN

Compugen (CGEN)

Compugen Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CGEN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
03/10/2023	06:00	PR Newswire (US)	Compugen to Present at Single Cell Genomics 2023 Meeting	NASDAQ:CGEN	Compugen Ltd
02/10/2023	06:00	PR Newswire (US)	Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	NASDAQ:CGEN	Compugen Ltd
27/09/2023	08:00	PR Newswire (US)	Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023	NASDAQ:CGEN	Compugen Ltd
21/09/2023	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
31/08/2023	06:00	PR Newswire (US)	Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference	NASDAQ:CGEN	Compugen Ltd
23/08/2023	07:00	Edgar (US Regulatory)	Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]	NASDAQ:CGEN	Compugen Ltd
07/08/2023	06:00	PR Newswire (US)	Compugen Reports Second Quarter 2023 Results	NASDAQ:CGEN	Compugen Ltd
24/07/2023	06:00	PR Newswire (US)	Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023	NASDAQ:CGEN	Compugen Ltd
17/07/2023	06:00	PR Newswire (US)	Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party	NASDAQ:CGEN	Compugen Ltd
23/06/2023	15:17	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-3/a)	NASDAQ:CGEN	Compugen Ltd
22/06/2023	06:01	Edgar (US Regulatory)	Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)	NASDAQ:CGEN	Compugen Ltd
22/06/2023	06:00	PR Newswire (US)	Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study	NASDAQ:CGEN	Compugen Ltd
13/06/2023	06:00	PR Newswire (US)	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CGEN	Compugen Ltd
05/06/2023	06:00	PR Newswire (US)	Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer	NASDAQ:CGEN	Compugen Ltd
15/05/2023	06:00	PR Newswire (US)	Compugen Reports First Quarter 2023 Results	NASDAQ:CGEN	Compugen Ltd
11/05/2023	06:00	PR Newswire (US)	Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023	NASDAQ:CGEN	Compugen Ltd
09/05/2023	06:00	PR Newswire (US)	Compugen to Present at the JMP Securities Life Sciences Conference	NASDAQ:CGEN	Compugen Ltd
01/05/2023	06:00	PR Newswire (US)	Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023	NASDAQ:CGEN	Compugen Ltd
27/04/2023	06:00	PR Newswire (US)	Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023	NASDAQ:CGEN	Compugen Ltd
26/04/2023	06:00	PR Newswire (US)	Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting	NASDAQ:CGEN	Compugen Ltd
30/03/2023	15:07	Edgar (US Regulatory)	Securities Registration (foreign Private Issuer) (f-3)	NASDAQ:CGEN	Compugen Ltd
15/03/2023	06:00	PR Newswire (US)	Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023	NASDAQ:CGEN	Compugen Ltd
08/03/2023	06:00	PR Newswire (US)	Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference	NASDAQ:CGEN	Compugen Ltd
06/03/2023	06:00	PR Newswire (US)	Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study	NASDAQ:CGEN	Compugen Ltd
28/02/2023	06:02	Edgar (US Regulatory)	Annual and Transition Report (foreign Private Issuer) (20-f)	NASDAQ:CGEN	Compugen Ltd
27/02/2023	06:00	PR Newswire (US)	Compugen Reports Fourth Quarter and Full Year 2022 Results	NASDAQ:CGEN	Compugen Ltd
14/02/2023	06:00	PR Newswire (US)	Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3	NASDAQ:CGEN	Compugen Ltd
13/02/2023	06:00	PR Newswire (US)	Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023	NASDAQ:CGEN	Compugen Ltd
10/02/2023	09:31	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:CGEN	Compugen Ltd
09/02/2023	06:00	PR Newswire (US)	Compugen to Present at the SVB Securities Global Biopharma Conference	NASDAQ:CGEN	Compugen Ltd